

Cambridge University Press
978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
Owen Bowden-Jones, Dima Abdulrahim
Frontmatter
[More Information](#)

Club Drugs and Novel Psychoactive Substances

Over the last decade many hundreds of new psychoactive drugs have emerged onto illicit markets. This flood of new drugs has led to clinicians being unsure of the rapidly emerging changing evidence base and uncertain of the best approaches to assessment and clinical management. This book provides a concise, accessible summary of these emerging drugs. By categorizing the hundreds of new drugs by their predominant psychoactive effect – sedative, stimulant and hallucinogenic – the book helps clinicians to manage a drug they are unfamiliar with by using their experience of other drugs with similar psychoactive properties. Written for clinicians from across the frontline, from A&E staff to drug treatment professionals, the authors draw on numerous clinical examples from their own clinical experiences to illustrate aspects of assessment and management. Club drugs and novel psychoactive substances will continue to challenge clinicians and this handbook provides readers with an invaluable introduction to this complex area.

Owen Bowden-Jones is Consultant in Addiction Psychiatry and Founder of the CNWL Club Drug Clinic, London, and Honorary Professor at University College London. He is Chair of the Advisory Council on the Misuse of Drugs and National Clinical Adviser to the Alcohol, Drugs and Tobacco division at Public Health England.

Dima Abdulrahim is Programme Manager and Principal Researcher for the NEPTUNE Project for the Club Drug Clinic, Central and North West London NHS Foundation Trust. She has been working in the drug treatment field for over 30 years.

Cambridge University Press

978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances

Owen Bowden-Jones , Dima Abdulrahim

Frontmatter

[More Information](#)

Cambridge University Press

978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances

Owen Bowden-Jones , Dima Abdulrahim

Frontmatter

[More Information](#)

Club Drugs and Novel Psychoactive Substances

The Clinician's Handbook

Owen Bowden-Jones

Central North West London NHS Foundation Trust

Dima Abdulrahim

Central North West London NHS Foundation Trust



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press
978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
Owen Bowden-Jones , Dima Abdulrahim
Frontmatter
[More Information](#)

CAMBRIDGE
UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom
One Liberty Plaza, 20th Floor, New York, NY 10006, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India
79 Anson Road, #06–04/06, Singapore 079906

Cambridge University Press is part of the University of Cambridge.
It furthers the University’s mission by disseminating knowledge in the pursuit of
education, learning, and research at the highest international levels of excellence.

www.cambridge.org
Information on this title: www.cambridge.org/9781911623090
DOI: 10.1017/9781911623106

© Cambridge University Press 2020

This publication is in copyright. Subject to statutory exception
and to the provisions of relevant collective licensing agreements,
no reproduction of any part may take place without the written
permission of Cambridge University Press.

First published 2020

Printed in the United Kingdom by TJ International Ltd, Padstow Cornwall

A catalogue record for this publication is available from the British Library.

Library of Congress Cataloging-in-Publication Data

Names: Bowden-Jones, Owen, author. | Abdulrahim, Dima, author.
Title: Club drugs and novel psychoactive substances : a clinical handbook / Owen Bowden-Jones,
Central North West London NHS Foundation Trust, Dima Abdulrahim, Central North West
London NHS Foundation Trust.
Description: Cambridge, United Kingdom ; New York, NY : Cambridge University Press, 2020. |
Includes bibliographical references and index.
Identifiers: LCCN 2020026282 (print) | LCCN 2020026283 (ebook) | ISBN 9781911623090
(paperback) | ISBN 9781911623106 (ebook)
Subjects: LCSH: Designer drugs. | Psychotropic drugs. | Drugs of abuse.
Classification: LCC RM316 .B69 2020 (print) | LCC RM316 (ebook) | DDC 615.7/88–dc23
LC record available at <https://lccn.loc.gov/2020026282>
LC ebook record available at <https://lccn.loc.gov/2020026283>

ISBN 978-1-911-62309-0 Paperback

Cambridge University Press has no responsibility for the persistence or accuracy of
URLs for external or third-party internet websites referred to in this publication
and does not guarantee that any content on such websites is, or will remain,
accurate or appropriate.

.....

Cambridge University Press

978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances

Owen Bowden-Jones , Dima Abdulrahim

Frontmatter

[More Information](#)

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

Acknowledgements x

Part I – Introduction	4	Classification Framework for Club Drugs and NPS	11
1 Introduction	1	5 The Clinical Challenge of Club Drugs and NPS	13
1.1 Why Read This Book?	1	5.1 Initial Assessment of the Health Harms of Club Drugs and NPS	13
1.2 Aim and Structure	2	5.2 Categorising Adverse Health Harms of Club Drugs and NPS	14
2 What Are Club Drugs and NPS and Why Are They Important?	3	5.3 Five Specific Clinical Challenges in Assessing Adverse Health Effects of Club Drugs and NPS	16
2.1 What Are Club Drugs and NPS?	3	5.4 Overview of the Management of Club Drug and NPS Harms	17
2.2 Club Drugs	4		
2.3 Novel Psychoactive Substances	4	Part II – Stimulant Drugs	
3 A Brief History of NPS Production and Distribution	5	6 Stimulant Drugs: Introduction	23
3.1 Overview	5	6.1 Introduction and Brief Pharmacology of Stimulant Drugs	23
3.2 Successive Generations of NPS	8	6.2 Desired Effects of Stimulants by User	24
3.3 Change and Continuity	8	6.3 Adverse Health Harms of Stimulants	24
3.4 Case Study: A Dynamic Market – the Rise and Fall of Mephedrone in the UK	8	6.4 Acute Health Harms of Stimulants	24
3.5 Evolving Drug Markets: New versus Traditional	9		
3.6 The Role of the Internet	9		

Cambridge University Press
 978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
 Owen Bowden-Jones, Dima Abdulrahim
 Frontmatter
[More Information](#)

6.5	Management of Acute Harms of Stimulants	25	9.3	Desired Effects by User	38
6.6	Serotonin Syndrome	26	9.4	Acute Health Harms	39
6.7	Health Harms from Repeated Use of Stimulants	28	9.5	Case Study: Methamphetamine-Induced Psychosis	39
6.8	Management of Harms from Repeated Use of Stimulants	29	9.6	Management of Acute Health Harms	42
7	Stimulant Drugs: Cocaine	31	9.7	Health Harms from Repeated Use	42
7.1	Introduction and Brief Pharmacology	31	9.8	Case Study: Chemsex-Related Sexually Transmitted Infection	42
7.2	Modes of Use	31	9.9	Methamphetamine Pro-sexual Effects	44
7.3	Desired Effects by User	31	9.10	Management of Health Harms from Repeated Use	45
7.4	Acute Health Harms	31	10	Stimulant Drugs: MDMA and Drugs with Similar Effects	46
7.5	Case Study: Cocaine User with Chest Pain	32	10.1	Introduction and Brief Pharmacology	46
7.6	Management of Acute Health Harms	33	10.2	Therapeutic Uses of MDMA	46
7.7	Health Harms from Prolonged Use	34	10.3	The Fall and Rise of MDMA in the UK	46
7.8	Case Study: Cocaine Dependence	34	10.4	Substitution of MDMA with Other Drugs	47
7.9	Management of Cocaine Dependence and Withdrawal Symptoms	36	10.5	Modes of Use	48
8	Stimulant Drugs: Amphetamine-Type Stimulants	37	10.6	Desired Effects by User	49
8.1	Introduction and Brief Psychopharmacology	37	10.7	Acute Health Harms	49
9	Stimulant Drugs: Methamphetamine	38	10.8	Management of Acute Health Harms	49
9.1	Introduction and Brief Pharmacology	38	10.9	Case Study: MDMA-Induced Serotonin Syndrome	51
9.2	Modes of Use	38			

Cambridge University Press
 978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
 Owen Bowden-Jones, Dima Abdulrahim
 Frontmatter
[More Information](#)

viii | Contents

- | | |
|--|--|
| <p>10.10 Health Harms from Repeated Use 52</p> <p>10.11 Management of Health Harms from Repeated Use 53</p> <p>11 Stimulant Drugs: Synthetic Cathinones 54</p> <p>11.1 Introduction 54</p> <p>11.2 Brief Pharmacology 54</p> <p>11.3 Modes of Use 55</p> <p>11.4 Desired Effects by User 56</p> <p>11.5 Acute Health Harms 56</p> <p>11.6 Management of Acute Health Harms 56</p> <p>11.7 Health Harms from Repeated Use 56</p> <p>11.8 Case Study: Mephedrone Injecting 57</p> <p>11.9 Management of Harms from Repeated Use 59</p> <p>Part II – Depressant Drugs</p> <p>12 Depressant Drugs: Introduction 61</p> <p>13 Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL) 62</p> <p>13.1 Introduction and Brief Pharmacology 62</p> <p>13.2 Modes of Use 62</p> <p>13.3 Desired Effects by User 63</p> <p>13.4 Acute Health Harms 63</p> <p>13.5 Case Study: Acute GHB Withdrawal 65</p> | <p>13.6 Management of Acute Health Harms 67</p> <p>13.7 Health Harms from Repeated Use 69</p> <p>13.8 Management of Health Harms from Repeated Use 70</p> <p>14 Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS 71</p> <p>14.1 Introduction 71</p> <p>14.2 Fentanyl and Fentanyl Analogues 72</p> <p>14.3 Other Opioid NPS (Excluding Fentanyls) 73</p> <p>14.4 Case Study: Fentanyl Overdose 75</p> <p>14.5 Management of Acute Health Harms of Fentanyls and Other Opioid NPS 76</p> <p>14.6 Health Harms from Repeated Use of Fentanyls and Other Opioid NPS 76</p> <p>14.7 Management of Health Harms from Repeated Use of Fentanyls and Other Opioid NPS 76</p> <p>15 Depressant Drugs: Benzodiazepine NPS 78</p> <p>15.1 Introduction and Brief Pharmacology 78</p> <p>15.2 Modes of Use 79</p> <p>15.3 Desired Effects by User 79</p> <p>15.4 Acute Health Harms 79</p> <p>15.5 Management of Acute Health Harms 80</p> |
|--|--|

Cambridge University Press
 978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
 Owen Bowden-Jones, Dima Abdulrahim
 Frontmatter
[More Information](#)

15.6 Health Harms from Repeated Use	80	17.7 Management of Acute Health Harms	93
15.7 Management of Health Harms from Repeated Use	80	17.8 Health Harms from Repeated Use	94
16 Depressant Drugs: Ketamine and Its Analogues	81	17.9 Case Study: SCRA Dependence in Homeless Population	95
16.1 Introduction	81	17.10 Management of Health Harms from Repeated Use	96
16.2 Brief Pharmacology	81		
16.3 Modes of Use	82	Part V – Hallucinogens	
16.4 Desired Effects by User	82	18 Hallucinogens	99
16.5 Acute Health Harms	83	18.1 Introduction	99
16.6 Management of Acute Health Harms	83	18.2 Brief Pharmacology	99
16.7 Health Harms from Repeated Use	84	18.3 Modes of Use	100
16.8 Case Study: Ketamine Bladder	85	18.4 Desired Effects by User	101
16.9 Management of Health Harms from Repeated Use	87	18.5 Acute Health Harms	102
Part IV – Synthetic Cannabinoid Receptor Agonists		18.6 Management of Acute Health Harms	103
17 Synthetic Cannabinoid Receptor Agonists (SCRAs)	89	18.7 Health Harms from Repeated Use	103
17.1 Introduction	89	18.8 Case Study: Hallucinogen Persisting Perception Disorder	104
17.2 Brief Pharmacology	89	18.9 Management of Health Harms from Repeated Use	106
17.3 Modes of Use	90		
17.4 Desired Effects by User	91	19 Concluding Remarks	107
17.5 Acute Health Harms	91		
17.6 Case Study: ‘Spice Attack’ in Prison	92	References	109
		Index	124

Cambridge University Press
978-1-911-62309-0 — Club Drugs and Novel Psychoactive Substances
Owen Bowden-Jones , Dima Abdulrahim
Frontmatter
[More Information](#)

Acknowledgements

Thanks to Sarah Finley for her assistance with the critical care sections.